版本:
中国

BRIEF-Cumberland reports new program to develop Portaban for Portal Hypertension

Sept 14 Cumberland Pharmaceuticals :

* Cumberland Pharmaceuticals announces new program to develop Portaban for Portal Hypertension

* U.S. FDA cleared Cumberland's investigational new drug application for multicenter, randomized, double-blind, placebo-controlled phase II clinical study Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐